Get the Stockscreener App
45.09
4.13%
1.79
After Hours:
44.77
-0.32
-0.71%
Sionna Therapeutics Inc stock is traded at $45.09, with a volume of 768.53K.
It is up +4.13% in the last 24 hours and up +20.82% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
See More
Previous Close:
$43.30
Open:
$44.23
24h Volume:
768.53K
Relative Volume:
2.47
Market Cap:
$2.03B
Revenue:
-
Net Income/Loss:
$-75.27M
P/E Ratio:
-26.58
EPS:
-1.6963
Net Cash Flow:
$-66.67M
1W Performance:
+22.03%
1M Performance:
+20.82%
6M Performance:
+45.88%
1Y Performance:
+373.63%
1-Day Range:
$42.62
$46.10
1-Week Range:
$36.23
$46.10
52-Week Range:
$9.24
$46.10
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
617-819-2020
Address
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
45.09 | 1.95B | 0 | -75.27M | -66.67M | -1.6963 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Citizens | Mkt Outperform |
| Dec-01-25 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
View All
Sionna Therapeutics Inc Stock (SION) Latest News
Sionna Therapeutics stock hits all-time high at 45.17 USD - Investing.com
SION Options Volatility — NASDAQ:SION - TradingView — Track All Markets
Aug Technicals: How Sionna Therapeutics Inc. stock reacts to global recession fearsDividend Hike & Fast Moving Stock Trade Plans - bollywoodhelpline.com
SION Options Chain — NASDAQ:SION - TradingView — Track All Markets
Is Sionna Therapeutics Inc undervalued by DCF analysisPortfolio Update Report & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Growth Value: Whats the MACD signal for Sionna Therapeutics Inc2026 Summary & Expert-Curated Trade Recommendations - baoquankhu1.vn
Gains Recap: Whats the outlook for Sionna Therapeutics Incs sector2026 Analyst Calls & Expert-Curated Trade Recommendations - baoquankhu1.vn
Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium - Bitget
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 4.4%Here's What Happened - MarketBeat
Dip Buying: Is Sionna Therapeutics Inc stock a buy or sell2026 Earnings & Step-by-Step Swing Trade Plans - baoquankhu1.vn
Aberdeen Group plc Sells 110,587 Shares of Sionna Therapeutics, Inc. $SION - marketbeat.com
Sionna Therapeutics, Inc.Common Stock (NQ: SION - The Chronicle-Journal
OrbiMed Advisors LLC sells Sionna Therapeutics (SION) stock worth $1.37m - Investing.com
Sionna Therapeutics Executive Sells Shares - Intellectia AI
Sionna Therapeutics CLO Divests All Direct Stock Holdings in March 2026News and Statistics - IndexBox
Sionna Therapeutics (NASDAQ:SION) Trading 8.8% HigherTime to Buy? - MarketBeat
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story - Yahoo Finance
Sionna Chief Legal Officer Cashed Out Her Shares. Her Options Are Another Story - The Motley Fool
Sionna Stock Is Up 144% This Past Year. Is the Biotech a Buy as One Fund Makes a $7 Million Bet? - aol.com
Aug PreEarnings: Should you avoid Sionna Therapeutics Inc stock right now2026 Catalysts & High Conviction Buy Zone Picks - baoquankhu1.vn
SION Forecast, Price Target & Analyst Ratings | SIONNA THERAPEUTICS INC (NASDAQ:SION) - ChartMill
Setup Watch: Is Sionna Therapeutics Inc currently under institutional pressureTrade Analysis Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
SION Technical Analysis | Trend, Signals & Chart Patterns | SIONNA THERAPEUTICS INC (NASDAQ:SION) - ChartMill
Sionna Therapeutics, Inc. (NASDAQ:SION) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Up 3.8%Here's What Happened - MarketBeat
JPMorgan Chase & Co. Lowers Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
This Investor Sold $5 Million of a Biotech Stock Up 118% in a Year, but Here's Why It Still Seems Bullish on Shares - AOL.com
Superstring Capital Invests in Sionna Therapeutics: Q4 2025 Filing DetailsNews and Statistics - IndexBox
'This is one of your classic, binary biotech stocks': Baral on Sionna Therapeutics - BNN Bloomberg
This investor offloaded $5 million worth of a biotech stock that surged 118% over the past year, yet there are still reasons to believe they remain optimistic about its future performance. - Bitget
Braidwell LP Has $9.24 Million Stake in Sionna Therapeutics, Inc. $SION - MarketBeat
Analysts Offer Insights on Healthcare Companies: Sionna Therapeutics, Inc. (SION) and Health Catalyst (HCAT) - The Globe and Mail
Sionna Therapeutics, Inc. $SION Shares Sold by Atlas Venture Life Science Advisors LLC - MarketBeat
SION: Advancing NBD1 stabilizers for cystic fibrosis with pivotal data expected by mid-2026 - TradingView
Analysts Are Bullish on These Healthcare Stocks: Sionna Therapeutics, Inc. (SION), Privia Health Group (PRVA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Loss Report: Is now the right time to enter Sionna Therapeutics IncMarket Risk Summary & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
Sionna Therapeutics chief legal officer sells shares for $347,018 By Investing.com - Investing.com Australia
Sionna Therapeutics chief legal officer sells shares for $347,018 - Investing.com
TD Asset Management Inc Grows Position in Sionna Therapeutics, Inc. $SION - MarketBeat
[144] Sionna Therapeutics, Inc. SEC Filing - Stock Titan
Reassessing Sionna Therapeutics (SION) Valuation After Recent Share Price Pullback And CF Pipeline Progress - simplywall.st
UBS Maintains Buy on Sionna Therapeutics, Inc. (SION) March 02, 2026 - Meyka
SION: NBD1 stabilization could transform CF care, with dual and add-on therapies advancing in clinical trials - TradingView
Sionna Therapeutics (NASDAQ:SION) Earns Buy Rating from BTIG Research - MarketBeat
Sionna Therapeutics (NASDAQ:SION) Shares Gap DownShould You Sell? - MarketBeat
Sionna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Sionna Therapeutics Inc Stock (SION) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):